Control of GVHD with Retained GVT

通过保留 GVT 控制 GVHD

基本信息

  • 批准号:
    8260364
  • 负责人:
  • 金额:
    $ 27.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2013-03-31
  • 项目状态:
    已结题

项目摘要

The goals of this Project are to enhance our understanding of graft vs host disease (GVHD) and graft vs tumor (GVT) reactions to gain greater insight into these complex biological reactions and to develop strategies which may be translated to the clinic. We will utilize a novel bioluminescent imaging strategy whereby cell populations of interest are labeled with the luciferase (luc) gene and emit light. Towards this end we have generated a unique gfp/luc transgenic mouse line to ensure uniform gene expression and availability of labeled cell populations. Trafficking and survival of luc* cells can be followed in real time with high precision and sensitivity. We will evaluate the GVHD inducing capacity of primary CD4+ and CDS* T cells with respect to the location of key events in GVHD induction. We hypothesize that GVHD develops through the spatial and temporal migration of lymphocytes to key sites whereby alloreactive cells proliferate and upregulate other cell surface molecules required for entry into GVHD target organs such as the gastrointestinal tract, skin and liver. Bioluminescent based imaging will be utilized to identify the major sites of GVHD induction to direct tissue sampling and characterization of the infiltrating cell populations by FACS and immunofluorescence. We will further explore cell populations known to have GVT reactivity yet with limited GVHD potential to compare and contrast the trafficking and survival characteristics of these cells to primary T cells. We will focus on the use of cytokine induced killer (CIK) and natural killer (NK) cells since both cell populations have been shown to not result in clinically significant GVHD in clinical trials and may promote GVT effects. This basic and translational project will provide insights into GVHD pathophysiology and characterize cell populations capable of GVHD and GVT effects that could be translated to the clinic where CIK cells are being explored in Project 1, This Project interacts with Projects 1,2,4,5,7 and 8 and utilizes all of the Cores.
该项目的目的是提高我们对移植物抗宿主病(GVHD)的认识

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert S Negrin其他文献

Treatment of donors with liposomal alpha-galactosylceramide results in the in vivo expansion of invariant natural killer T cells and reduced incidence of acute graft versus host disease
用脂质体 α-半乳糖神经酰胺治疗供体可导致不变自然杀伤 T 细胞体内扩增,并降低急性移植物抗宿主病的发生率
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Toshihito Hirai;Federico Simonetta;Kristina Mass-Bauer;Jeanette Baker;Mustafa Tukoz;Maite Alvarez;Melissa Mavers;Robert S Negrin
  • 通讯作者:
    Robert S Negrin

Robert S Negrin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert S Negrin', 18)}}的其他基金

Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    9065603
  • 财政年份:
    2012
  • 资助金额:
    $ 27.39万
  • 项目类别:
Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    8903997
  • 财政年份:
    2012
  • 资助金额:
    $ 27.39万
  • 项目类别:
Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    8534275
  • 财政年份:
    2012
  • 资助金额:
    $ 27.39万
  • 项目类别:
Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    8701379
  • 财政年份:
    2012
  • 资助金额:
    $ 27.39万
  • 项目类别:
Regulatory T cells in allogeneic transplantation
同种异体移植中的调节性T细胞
  • 批准号:
    8343992
  • 财政年份:
    2012
  • 资助金额:
    $ 27.39万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 27.39万
  • 项目类别:
Hematopoetic
造血
  • 批准号:
    8181092
  • 财政年份:
    2010
  • 资助金额:
    $ 27.39万
  • 项目类别:
Regulatory T Cells in Allogeneic Transplantation
同种异体移植中的调节性 T 细胞
  • 批准号:
    7939868
  • 财政年份:
    2009
  • 资助金额:
    $ 27.39万
  • 项目类别:
Regulatory T Cells in Allogeneic Transplantation
同种异体移植中的调节性 T 细胞
  • 批准号:
    7855234
  • 财政年份:
    2009
  • 资助金额:
    $ 27.39万
  • 项目类别:
NK Cells in GVHD and GVT
GVHD 和 GVT 中的 NK 细胞
  • 批准号:
    7673379
  • 财政年份:
    2008
  • 资助金额:
    $ 27.39万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 27.39万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 27.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了